Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunhee Kang

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Bioorganic & Medicinal Chemistry|October 19, 2020
Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agentGuanghai Jin, Young Mi Kim, Aram Lee, et al.
Journal of Medicinal Chemistry|May 30, 2014
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agentSunhee Kang, Ryang Yeo Kim, Min Jung Seo, et al.
Molecular Therapy. Nucleic Acids|December 15, 2025
Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiencyJiyeon Son, Hyunjung Yoo, Joonyoung Park, et al.
Molecular Therapy. Nucleic Acids|December 30, 2025
Erratum: Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiencyJiyeon Son, Hyunjung Yoo, Joonyoung Park, et al.
Plos Pathogens|October 31, 2009
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitorsThierry Christophe, Mary Jackson, Hee Kyoung Jeon, et al.
Nature Medicine|August 6, 2013
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosisKevin Pethe, Pablo Bifani, Jichan Jang, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Bioorganic & Medicinal Chemistry|October 19, 2020
Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agentGuanghai Jin, Young Mi Kim, Aram Lee, et al.
Journal of Medicinal Chemistry|May 30, 2014
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agentSunhee Kang, Ryang Yeo Kim, Min Jung Seo, et al.
Molecular Therapy. Nucleic Acids|December 15, 2025
Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiencyJiyeon Son, Hyunjung Yoo, Joonyoung Park, et al.
Molecular Therapy. Nucleic Acids|December 30, 2025
Erratum: Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiencyJiyeon Son, Hyunjung Yoo, Joonyoung Park, et al.
Plos Pathogens|October 31, 2009
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitorsThierry Christophe, Mary Jackson, Hee Kyoung Jeon, et al.
Nature Medicine|August 6, 2013
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosisKevin Pethe, Pablo Bifani, Jichan Jang, et al.
Pageof 2